title: [EXPERIENCE OF USE OF BLEMAREN® IN THE TREATMENT OF PATIENTS IN URIC ACID AND CALCIUM OXALATE UROLITHIASIS].
abstract: 154 patients with urolithiasis were under outpatient observation for 2-8 years. Among them there were 76 women and 78 men aged 21-66 years, of which 46 patients with uric acid urolithiasis, and 88--with calcium oxalate urolithiasis. Treatment of patients was carried out systematically, depending on their condition. Indications for the application of Blemaren® included the presence of uric acid stones, uric acid and/or oxalate crystalluria. The duration of treatment was 6.1 months. The dosage of the drug varied from 6 to 18 g per day and was selected individually, depending on the purpose of the appointment of Blemaren®. Reduction of the urine pH to 6.2- 6.8-7.2 was the criterion for properly selected dose. To dissolve uric acid stones in the presence of hyperuricemia and/or hyperuricuria, Blemaren® was administered in combination with allopurinol at a dose of 0.1 g 3-4 times a day. Besides pharmacotherapy, treatment included diet therapy. It was found that the morning urine pH in urate urolithiasis is sustainable and has a range of 5.0-6.0, in 80.4% of cases--range of 5.0-5.5. In calcium oxalate urolithiasis this parameter is also stable and has a range of 5.0-6.7, in 82.9% of cases--range of 5.5-6.0. Optimal urine pH to eliminate uric acid and oxalate crystalluria in patients with uric acid and calcium oxalate urolithiasis is the interval of 6.2-6.4. It was shown that Blemaren® is a highly effective agent for treatment and prevention of uric acid and calcium oxalate crystalluria in calcium oxalate and uric acid urolithiasis. Further, its effectiveness in dissolving of uric acid stones in the absence of an infectious inflammatory process is 82.3%.
authors: O V
authors: OV
authors: Konstantinova
authors: E K
authors: EK
authors: Yanenko
mesh_terms: D000328:Adult; D000368:Aged; D001639:Bicarbonates / Q000008:administration & dosage*; D002129:Calcium Oxalate / Q000652:urine*; D002951:Citrates / Q000008:administration & dosage*; D019343:Citric Acid / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017680:Potassium Compounds / Q000008:administration & dosage*; D000077559:Sodium Citrate; D014527:Uric Acid / Q000652:urine*; D052878:Urolithiasis / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology
chemical_list: D001639:Bicarbonates; D002951:Citrates; D017680:Potassium Compounds; D000077559:Sodium Citrate; D002129:Calcium Oxalate; D014527:Uric Acid; D019343:Citric Acid; C026329:potassium bicarbonate